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of proteins participating in collagen/elastin biogenesis and immune markers in vaginal
tissues of post‐menopausal women with severe pelvic organ prolapse (POP). Vaginal
biopsies were collected from the anterior vaginal wall of informed and consented 52
post‐menopausal women with severe POP undergoing total hysterectomy. Twenty‐
nine of the 52 women were treated with LET (in the form of vaginal oestrogen cream
or tablet), while the remaining 23 untreated patients served as the controls. This
study was approved by Sinai Health System REB. Vaginal tissue specimens were ana‐
lysed for gene and protein expression using real‐time RT‐PCR and Luminex assays,
protein localization and immune cell infiltration were assessed by immunohistochem‐
istry. Forty‐four cytokines were detected. We found that LET application: (a) signifi‐
cantly increased (P < 0.05) gene and protein expression levels of extracellular matrix
(ECM) structural proteins, collagen and elastin, as well as the expression of ECM
maturation enzyme BMP1; (b) decreased protein expression level of ECM degrada‐
tion enzymes MMP1, MMP2 and MMP3 accompanied by an increase in their tissue
inhibitors, TIMP1 and TIMP4; (c) significantly increased (P < 0.05) the gene and pro‐
tein expression levels of 14 vaginal cytokines involved in leucocyte infiltration, which
was confirmed by immunohistochemistry. Our results indicate that LET plays an im‐
portant role in the activation of immune system within the local vaginal environment,
limiting the undesirable ECM degradation, which supports the strengthening of vagi‐
nal ECM in post‐menopausal women, therefore resisting menopause/age‐related
changes and inducing urogenital tract tissue regeneration.
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1 | I NTRO D U C TI O N

known as PCP), and higher degradation activity with an increase in
matrix metalloproteases (MMPs) expression and activity and a de‐

Pelvic organ prolapse (POP) represents a major health issue for

crease in tissue inhibitors of MMP (TIMPs).16,17 Importantly, there is

women worldwide and affects nearly 50% of the population of

extensive literature affirming that the immune system plays a role in

post‐menopausal women.1 Multiple risk factors that lead to POP

extracellular matrix (ECM) regulation. For instance, mice deficient in T

also include race, parity, obesity and chronic conditions (cough,

and B cells exhibit decreased total and cross‐linked collagen and LOX,

constipation) that result in higher pressure on the pelvic floor. POP

and at the same time, increased MMP2, suggesting a role of lympho‐

is the most common reason for hysterectomy among post‐meno‐

cytes in ECM remodelling.18

pausal women.

2,3

Management options for POP include observa‐

In pre‐menopausal women, hormonal regulation affects

tion, pessary use and urogynaecologic surgery. The lifetime risk for

the expression of multiple genes regulating immune cell com‐

undergoing at least one operation for POP is 11.1%, however, the

position in the vagina, and endocrine balance in the mucosal

re‐operation rates are as high as 29%. With an ageing population,

immune system.19,20 However, this type of regulation is not pres‐

the demand for POP operations is expected to rise in the future. 2

ent in post‐menopausal women. Changes in the immune system

Local oestrogen therapy (LET) is clinically used as an aid in POP

a ccompanying ageing and oestrogen deprivation are known as

treatment. In particular, as hypoestrogenism is a major risk factor

immunosenescence, the process characterized by a decrease in

for POP, some expert gynaecologic surgeons recommend pre‐ and/

cell‐mediated immune function and humoral response 21 which is

or post‐operative vaginal oestrogen therapy for post‐menopausal

reflected by a higher incidence of chronic infectious disease in

3,4

Importantly, the severity of POP symptoms has been

post‐menopausal women. 22 Studies have shown that hormone re‐

shown to increase after menopause, which suggests that hypoestro‐

placement therapy (HRT) in post‐menopausal women can improve

genism may be a contributory factor for the development of POP.5,6

wound healing, modulate cytokine production and proliferation

However, there is no consensus in the medical community about

of immune cells. 23,24 It appears that oestrogen plays an import‐

the efficacy of prescribing LET to patients with prolapse leading to

ant role in restoring altered immune profile with normal ageing

a difference in patient care. There are few studies available, which

peri‐menopausal women, suggesting that preservation of immune

directly address the effect of vaginal oestrogen on POP to ascer‐

function may be supported by systemic HRT. Despite these known

tain the theoretical basis for its therapeutic application. Circulatory

effects of oestrogen, not much work has been done to examine

levels of oestrogen in females change in a monthly cyclic pattern

the effect of LET on the immune system of patients with POP.

during reproductive years. At menopause, however, oestrogen levels

Thus, the objective of this study was to investigate the effect of

women.

in the blood decrease significantly from 15‐350 pg/mL (menstruat‐

LET (oestrogen cream or tablet) on the expression of proteins par‐

ing women) to 6.5 pg/mL (post‐menopausal women).7,8 Deficiency in

ticipating in collagen/elastin biogenesis and on modulation of im‐

oestrogen following menopause affects reproductive organs, caus‐

mune response in vaginal tissues of post‐menopausal women with

ing vaginal dryness, and reduction in vaginal weight.9 These vaginal

severe POP.

and urinary symptoms are defined as the genitourinary syndrome of
menopause (GSM). Oestrogen plays a supportive role in the pelvis
by controlling the synthesis and breakdown of collagen.10 Oestrogen
receptors α and β (ESR1/2) are present throughout the lower uri‐
nary tract, bladder and vagina; with ESR1 being the predominant
isoform.11 They are expressed in three vaginal layers (epithelium,

2 | M ATE R I A L S A N D M E TH O DS
2.1 | Patient selection
The Research Ethics Board of Mount Sinai Hospital, Toronto approved

lamina propria and muscularis), and are responsive to steroid hor‐

this study (05‐0193‐E). Vaginal biopsy samples were collected from

mones.12 Oestrogen therapy has been prescribed to treat urinary

post‐menopausal women undergoing vaginal hysterectomy for POP

symptoms related to urogenital atrophy, such as vaginal dryness, ir‐

following informed consent. All patients had grade 3‐4 of prolapse

ritation or itching, dyspareunia and thin and frail epithelium.15 ESRs

as per POP‐Q classification. The POP patients were either receiving

are also found on a variety of immune cells through which estradiol

local oestrogen therapy (LET group, n = 29) through oestrogen cream

plays an important role in the regulation of the immune system.13,14

(Premarin) or tablets (Vagifem) or were not receiving oestrogen ther‐

Additionally, studies have reported a connection between the de‐

apy (No‐LET control group, n = 23). Premarin cream was taken once

velopment of POP and abnormalities in connective tissue structure and

daily (0.5 g) for 10 days, then twice weekly continuously until surgery;

repair mechanisms, such as in generalized connective tissue disorders

Vagifem tablet was taken one tablet once daily for 2 weeks (10 μg)

like Ehlers Danlos or Marfan syndrome.16 We have previously shown
that the weakened pelvic floor may arise from aberrant biosynthesis

then twice weekly until surgery day. Women with a history of gynae‐
cological malignancy, connective tissue disorders were excluded.

and biodegradation of structural proteins of the connective tissue.
POP patients have lower levels of structural proteins, and maturation
enzymes, including lysyl oxidase (LOX) family of enzymes, ADAMTS2

2.2 | Tissue collection

(A Disintegrin and Metalloproteinase with Thrombospondin motifs 2,

The tissue biopsy technique used in this study has been described

also known as PNP) and bone morphogenetic protein‐1 (BMP‐1, also

previously. 25 Full‐thickness vaginal wall biopsy (approximately

|

TYAGI et al.

1 cm2) was obtained from the anterior middle portion of the
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transcribed to cDNA (1 μg of RNA in 20 μL reaction) using iScript

vaginal vault and placed in ice‐cold PBS solution. One part of

supermix (Bio‐Rad, Canada) to produce cDNA at a final concentra‐

the vaginal biopsy was fixed in formalin for histological and im‐

tion of 50 ng/μL.

munohistochemical analyses, the second part was flash‐frozen in
liquid nitrogen and stored for biochemical assays (RNA extraction
for gene expression analysis, proteins extraction for Luminex and
enzyme‐linked immunosorbent assay [ELISA]). Due to some vari‐

2.4 | Real‐time RT‐PCR
Five nanograms of cDNA was mixed with SYBR® green PCR ready

ability in the size of the sample, sometimes tissue biopsy was used

mix (Sigma‐Aldrich, Canada) and specific primer pairs (Table 1).

only for one application.

Reverse transcription (RT)‐PCR was performed with the CFX384
Touch™ RT‐PCR detection system. A no‐template control was

2.3 | RNA extraction & reverse transcription
Frozen tissue samples were crushed and total RNA was extracted

used to control for any contaminations in a mastermix. PCR reac‐
tions were set up in triplicates and the cycle threshold (Ct) value
was recorded for each primer pair by CFX Manager software (Bio‐

using Trizol (Gibco, Canada) according to the manufacturer's pro‐

Rad). The expression level of target genes was normalized to the

tocol. RNA samples were purified using RNeasy MiniElute Cleanup

geometric mean of three housekeeping genes: TBP, SDHA and

Kit (Qiagen, Canada) and treated with 2.5 μL DNase I (Qiagen) to

YWHAZ, and a comparative Ct method (∆∆CT) was used to get

remove genomic DNA contamination. Total RNA was then reverse

relative gene expression values. All mRNA levels for LET‐treated

TA B L E 1 Real‐time PCR primer sequences of a panel of human genes encoding collagens, elastin and elastin‐related proteins, enzymes
involved in their maturation (LOX family) and cytokines
Symbol

Accession no.

Forward

Reverse

COL1

NM_000088.3

GCACCATCATTTCCACGAGC

GTCAGATGGGCCCCCG

COL3

NM_205380.2

GGTAGTCTCACAGCCTTGCG

GAGGATGGTTGCACGAAACAC

COL4

NM_001845.5

TGGGAAACCTTTTGGGCCTG

TAGGCACAGGACCTTTGGGA

COL5

NM_000093.4

TCCGAAGGGGCCAGAATCA

GAGCAGTTTCCCACGCTTGA

ADAMTS2

NM_014244.4

GTGTGCACCTGGCAAGCATTGTTT

AGCCAAACGGACTCCAAGCGC

BMP1

NM_001199.3

GCCACATTCAATCGCCCAA

TGGCGCTCAATCTCAAAGGAC

LOX

NM_002317.6

GGCGAAGGGTGAGGAGTAAG

TGGGAGACCTAAACGTCAGC

LOXL1

NM_005576.3

TATGTCCAGAGAGCCCACCT

TAGCACCCGCACATCGTAGT

LOXL2

NM_002318.2

ATGTCACCTGCGAGAATGGG

TGCTCTGGCTTGTACGCTTT

LOXL3

NM_001289164

TCAGCCAGAAAGGCAAGGAG

GGGGACGAGAAACACTGACC

ELN

NM_000501.3

CCTCCCTTCTGCTTCCTCTC

CGACTGTTCTTTCGCTGCTG

FBN1

NM_000138.4

TCTGCACAAAAACGCTCTGC

CTCCCGTGCGGATATTTGGA

FBN2

NM_001999.3

CTCTTCTTCTGGGGGCGACTT

CGCTCCGAAGACGGATATTGG

FBLN5

NM_006329.3

TCTGGAAAGGGCAGCAACTT

CTTGTCTATCAGCCGATGCG

MIF

NM_002415.1

CTCCACCTTCGCCTAAGAGC

TTCTCCCCACCAGAAGGTTG

IL16

NM_004513.5

TCTACAGCAGAGGCCACAGT

GAGGCTTGTCTCCGTGTAGG

IFN‐y

NM_000619.2

TCAAACCGGCAGTAACTGGAT

GGCAGCCAACCTAAGCAAGA

CX3CL1

NM_002996.4

CGGTGTGACGAAATGCAACA

CCGCATGATGCCTGGTTCT

CCL3

NM_002983.2

TCCGTCACCTGCTCAGAATCA

GATGCAGAGAACTGGTTGCAGA

CXCL12

NM_199168.3

CTTTCCGCTAGACCCACTCG

CTCATGGTTAAGGCCCCCTC

IL1b

NM_000576.2

CCATCAGCCAGGACAGTCAG

TCAGGCGGGCTTTAAGTGAG

CCL21

NP_002980.1

CTGGACAAGACACCATCCCC

CTCAGTCCTCTTGCAGCCTTT

IL8

NM_000584.3

AAACATGACTTCCAAGCTGGCCGT

GCAAAACTGCACCTTCACACAGAGC

IL6

NM_000600.4

TGGCTTGTTCCTCACTACTCT

TCAATGAGGAGACTTGCCTG

CXCL9

NM_002416.2

TAAGCGCTAGAGGAAGCAGC

CCCTGGAAGGAGGTTTCCAC

MIP1b

NM_002984.3

GTCTGTGCTGATCCCAGTGA

CAGGTGACCTTCCCTGAAGAC

TBP

NM_003194.4

CCACAGCTCTTCCACTCACA

CTGCGGTACAATCCCAGAAC

YWHAZ

NM_003406.3

CCGCCAGGACAAACCAGTAT

ACTTTTGGTACATTGTGGCTTCAA

SDHA

NM_004168.3

CCACCACTGCATCAAATTCATG

TGGGAACAAGAGGGCATCTG
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TA B L E 2
analyses

Summary of antibodies used in immunohistochemical

and pictures were imported into Visiopharm NewCast Software
(version 6.6.1.2572) EngineTM for quantification. The operator
was blinded to the treatment groups to prevent bias. The ‘Region

Antibody

Dilution

Source

Company

SMA

Monoclonal

1:50

Rabbit

Abcam

Collagen I

Polyclonal

1:100

Rabbit

Abcam

Collagen III

Polyclonal

1:1000

Rabbit

Abcam

Collagen V

Polyclonal

1:50

Rabbit

Abcam

CD45

Monoclonal

1:200

Mouse

Dako

formly spaced points. The area of total collagen and total elastin

CD68

Monoclonal

1:200

Mouse

Dako

was measured within each sampling area by number of grid points

Anti‐rabbit IgG

Polyclonal

1:200

Goat

Dako

overlying on collagen [blue staining] or elastin [black staining] and

Anti‐mouse IgG

Polyclonal

1:200

Goat

Dako

compiled to give the total area for collagen and elastin for each

of Interest’ was identified on the individual vaginal tissue sam‐
ple (Lamina Propria, LP or Muscularis layer, M) using a masking
tool and the total area was recorded in two replicates for same
biological sample. The section was divided into smaller sampling
areas (n = 20 per region of interest) using a grid consisting of uni‐

tissue. The relative amount of collagen and elastin for each tis‐
sue was calculated as the ratio of total area for collagen or elastin
post‐menopausal POP patients were expressed as fold changes

to the total area of region of interest (relative collagen content =

relative to mRNA levels in the vaginal tissue of the control non‐LET‐

total collagen area in tissue/area of tissue; relative elastin content

treated POP patients.

= total elastin area/area of tissue). These relative quantities were
compared between the LET and Control (No‐LET) groups (n = 10/

2.5 | Luminex protein assay
Frozen vaginal tissue samples (n = 19 per group) were crushed
and total protein was extracted using Bicine lysis buffer (Sigma‐
Aldrich). Tissue MMPs, TIMPs and cytokine levels were quanti‐

group).

2.8 | Immunohistochemistry
Tissue samples were fixed in 10% neutral buffered formalin or 4%

fied in vaginal tissue samples (500 μg) using Bio‐Plex Pro™ Human

paraformaldehyde and embedded in paraffin. Following rehydra‐

9‐Plex MMP assay, Human 4‐plex TIMP assay and Bio‐Plex ProTM

tion and quenching (3% H2O2), antigen retrieval was performed by

Human Cytokine Assays (40‐plex) in combination with a custom de‐

microwaving slides in 10 μM sodium citrate solution for 20 min‐

signed 5‐plex (all Bio‐Rad), following manufacturer's instructions.

utes (pH 6). Following the retrieval, slides were blocked using

The standard and sensitivity of all cytokines used are reported in

protein blocking solution (DAKO) and then incubated overnight at

Table S1. Tissue samples, standards and controls were analysed in

4°C with primary antibody (Table 2). For a negative control, non‐

duplicates. The plates were read on Bio‐Plex® 200 System instru‐

specific rabbit IgG (DAKO) was used at the same concentration as

ment with high‐throughput fluidics and analysed using the Bio‐Plex

primary antibody. Next, sections were incubated with biotinylated

ManagerTM 5.0.

secondary antibodies followed by Streptavidin‐HRP. Finally, tis‐
sue sections were mounted with Surgipath Micromount ® mount‐

2.6 | Enzyme‐linked immunosorbent assay

ing media (Leica Microsystems Inc.) and examined on an Olympus
BX61 Motorized Microscope and MicroSuite™ system (Olympus

Human IL‐1RA Duoset Elisa kit (R&D Systems, Minneapolis, MN,

America Inc.). The operator was blinded to the treatment groups

USA) was used to measure protein expression levels in human vagi‐

to minimize operator bias. A minimum of five fields were examined

nal tissues (N = 19/group), as instructed by the manufacturer's pro‐

and photographed for each tissue section using Olympus DP72

tocol. Based on the standard range of the ELISA kit, tissue samples

Microscope Digital Camera (Olympus America Inc.). The number

were diluted to ensure the absorbance of readings stayed within the

of positively stained immune cells were counted by the blinded

linear range of standard curve. The plate was read using μQuantTM

operator and recorded to quantify the infiltration of immune cells

(BioTek Instruments Inc.) with wavelength settings specified by the

into the tissue.

®

ELISA kit manufacturer.

2.7 | Histochemical analysis of total
collagen and elastin

2.9 | Statistical analysis
Statistical analysis was performed with independent sample t test
for continuous data and chi‐squared test for categorical data. Graphs

Vaginal tissue biopsy samples fixed in formalin were embedded in

were presented as mean ± SEM. The level of significance was set at

paraffin, cut into 5 μm slides and stained with a modified Masson's

P < 0.05 (*), P < 0.01 (**), and P < 0.001 (***). GraphPad Prism ver‐

Trichrome stain to measure the total protein content of collagen

sion 5.0 was used for all statistical analysis (GraphPad Software Inc,

and elastin. Verhoff's haematoxylin stain was used to stain elastic

USA). For experiments involving a subset of all samples collected, an

fibres black and Biebrich scarlet‐acid fuchsin was used to stain col‐

online random number generator was used to select for the samples

lagen green‐blue. All slides were scanned at 400× magnification,

without bias.
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3 | R E S U LT S

P = 0.24). The gene expression level of ECM maturation enzyme

3.1 | Patient demographics

No‐LET group. In contrast, expression of ADAMTS2 and LOX family

BMP1 showed a significant increase (P < 0.05) in LET as compared to

Fifty‐two post‐menopausal women with severe POP were recruited
into the study. Twenty‐nine of these women were using LET, while
23 women did not undergo any hormonal therapy (Control, No‐LET).
Groups were matched for age (mean age 64 vs 67 years), mean BMI
(26.2 vs 26.1) and median parity (2 vs 2). The majority (79%) of the
women recruited for this study had Stage III prolapse, with some
(21%) with Stage IV prolapse. The duration of LET for the post‐
menopausal women ranged from 1 to 24 months, with an average
of 8 months (Table 3).

members (LOX, LOXL‐1,2,3) did not differ significantly between the
two groups (Figure 1D).

3.3 | Immunohistochemical localization of
ECM proteins
Firstly, using histologic haematoxylin, eosin staining and α‐smooth
muscle actin (ACTC1) immunostaining, we confirmed the mor‐
phology of vaginal biopsy which included three anatomical layers:
stratified squamous epithelial (SSE), LP and muscularis (M). The rep‐

3.2 | Effect of LET on ECM biosynthesis and
biodegradation
Transcript levels of ECM structural and remodelling genes: col‐
lagens (COL1,3,4,5), elastin (ELN), proteins involved in elastin as‐
sembly fibrillin1 and 2 (FBN1, FBN2) and fibulin5 (FBLN5), ECM
maturation enzymes (LOX, LOXL1‐3, BMP1 and ADAMTS2), and
oestrogen receptors (ESR1, ESR2) were examined. We found the
presence of mRNA of both oestrogen receptor isoforms (ESR1
and ESR2) in human vagina. There was no significant difference
in the expression of either transcript between LET vs No‐LET
groups, indicating that LET does not influence ESR receptor level
(Figure 1A).
Among the genes encoding ECM structural proteins, the expres‐
sion level of three major structural collagens (COL1, COL3, COL5)
showed an increase in the mRNA levels in the vaginal tissues of LET
patients as compared to No‐LET POP patients (Figure 1B, P < 0.05).
COL4 transcript levels were increased in LET‐treated tissues, how‐
ever the difference did not reach significance (P = 0.076). In addi‐
tion, there was a significant increase in the expression of ELN gene
after treatment with LET (Figure 1C, P < 0.05). Transcript levels of
proteins involved in the deposition and maturation of elastin fibres,
FBN1 and FBN2 showed a significant increase, while FBLN5 showed
no significant difference between the two study groups (Figure 1C,

resentative images for each stain are shown at Figure S1. Next, spe‐
cific antibodies for ECM structural proteins (anti‐Collagen I, III and
V) were used to establish their tissue localization on full‐thickness
vaginal biopsies (n = 5 per group). The immunolabelling shows that
the majority of collagens were localized within the lamina propria,
some staining was detected in the muscularis layer in between the
muscle bundles, however, no collagen immunostaining was detected
in the SSE layer (Figure 2).

3.4 | Total Collagen and Elastin content evaluation
The modified Masson's Trichrome staining showed the expression
and localization of total collagen (blue) and elastin (black) proteins
in vaginal tissues, in particular their distribution across two layers
of vaginal biopsies (i.e. LP and M), but not in the SSE layer (Figure 3).
Quantification of the total protein content for both structural mol‐
ecules showed that LET caused a significant increase (P < 0.05) in
the content of collagen and elastin (1.53‐ and 2.29‐fold change
respectively) in vaginal samples of post‐menopausal women with
severe POP.

3.5 | Effect of LET on ECM degradation enzymes
We analysed protein tissue lysates extracted from vaginal biopsy
samples of post‐menopausal POP patients by high‐throughput
approach, bead‐based 9‐plex MMP assay and 4‐plex TIMP 1‐4

TA B L E 3

Summary of patients’ demographics

assay (Bio‐Rad) on the Luminex 200 platform. An equal amount
of total proteins (500 μg), was used to test the expression levels

Study groups

No‐LET

LET

n

19

19

Mean age

65 ± 7

66 ± 7

Mean BMI

25.8 ± 3.7

25.5 ± 3.8

tected. As we reported previously, 25 of the four MMP inhibitors,

Median parity

2 (1‐5)

2 (1‐7)

TIMP1 and TIMP2 protein levels showed the highest abundance

Duration of LET
(month)

0

8 (1‐24)a

Stage of POP (n)

Stage III (n = 16)
Stage IV (n = 3)

of multiple MMP and TIMP proteins. Data sets with extrapolated
concentration values outside the limit of the standard curves were
excluded from further analysis. All nine MMP proteins were de‐

in vaginal tissue from patients with severe POP. TIMP4 expression
was very low in human vagina. Samples from LET‐treated patients

Stage III (n = 14)
Stage IV (n = 5)

T test; level of significance: P < 0.05.
BMI, Body mass index; POP, pelvic organ prolapse.
a
Statistical significance between No‐LET and LET groups.

showed a significant decrease in the levels of MMP1, 2 and 3 pro‐
teins (Figure 4A, P < 0.05) and a significant increase for TIMP1 and
TIMP4 (P < 0.05), while MMP7‐10, 12 13, as well as TIMP2 and 3
showed no change in protein expression in response to oestrogen
(Figure 4B).
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F I G U R E 1 Gene expression of
extracellular matrix genes in vaginal
biopsies of post‐menopausal POP
patients. A, Transcript levels of Oestrogen
Receptors (EST1, EST2), (B) Collagens
(COL1, 3, 4, 5); (C) Elastin (ELN) and
Elastin‐related proteins (FBN1, FBN2,
FBLN5); (D) ECM maturation enzymes
(LOX, LOXL1‐4, ADAMTS2, BMP1). Data
presented as fold change in LET‐treated
group (black bars, N = 29) compared
to no LET (control, white bars, N = 23).
Statistical analysis was performed with
independent sample t test. A significant
difference is indicated by * (P < 0.05), **
(P < 0.01)

3.6 | Effect of LET on cytokine protein expression
Next, the expression of 45 cytokine proteins was analysed in vagi‐

cytokines/chemokines play important roles in innate and adaptive
immunity by inducing the migration or differentiation of immune
cells. Interestingly, macrophage inhibitory factor/MIF had the high‐

nal tissue samples from post‐menopausal POP patients and 44 cy‐

est level of expression among all chemokines studied in the panel

tokines were detected (Figure 5A and Table S2). All of the detected

(excluding IL‐1RA) with concentrations as high as 0.4 mg/mg of total

TYAGI et al.
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F I G U R E 2 Immunohistochemical
localization of Collagen I, III, and V
within human vaginal biopsy samples of
post‐menopausal women with severe
POP. Shown are representative images of
vaginal tissues from POP patients treated
with LET and no‐treated controls. The
immunolabelling for collagen proteins is
indicated by brown deposit. Magnification
is 200×; scale bar 50 μm. Negative control
is shown on Figure S1
protein (439 023.1 ± 53 111.5 pg/mg). CCL21 (chemoattractant for

cytokines, 14 showed a significant increase in LET‐treated samples:

activated T cells) showed the highest levels of expression among

CCL2/MCP1, CCL3/MIP1a, CCL4/MIP‐1B, CCL5/RANTES, CCL8,

CC family of chemokines (21 570.8 ± 2852.0 pg/mg). Interleukin

CCL19, IL‐8/CXCL8, IP‐10/CXCL10, CXCL12, CXCL13, IL‐1B, IL‐6,

(IL)‐16 (activator for T cells) also showed high levels of expression

IL‐16, G‐CSF, TNF‐α and IFN‐γ (P < 0.05, unpaired t test) (Figure 5B).

(1972.0 ± 193.4 pg/mg), while IL‐2, IL‐10, IL‐4, CCL20, CXCL13 and

These chemokines play important roles in the innate and adaptive

IFN‐γ proteins were detected at very low levels.

immunity within vaginal tissue by mediating the inflammatory re‐

Next, we compared the expression levels of the above cytokines

sponse (IL‐16, IFN‐γ, IL1B, TNF‐α), or inducing chemotaxis of mono‐

between LET‐treated and No‐LET women. Among the 44 detected

cytes/macrophages (MIP1b, IFN‐γ, IL‐16, IP‐10, CCL2, CCL3, CCL5,
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3.7 | Immunohistochemical assessment of leucocyte
infiltration
As the vast majority of chemokines up‐regulated by LET are chem‐
oattractants for immune cells, we next investigated whether they
can induce the infiltration of leucocytes into human vaginal tissue.
As we suggested, immunohistological staining for pan‐leucocyte
marker CD45 showed a significant increase in the infiltration of im‐
mune cells in vaginal samples from LET group, with majority of cells
localized to sub‐SSE (Figure 6A). There were 175 ± 38 vs 77 ± 17
CD45+ cells/mm2 (P < 0.05) in the sub‐SSE space of vaginal tissue
samples from LET‐treated patients vs No‐LET controls. Muscularis,
by contrast, had much fewer cells in LET‐treated vs control vaginal
samples.
As protein expression analysis showed a significant increase in
concentration of specific chemokines capable of attracting CD68+
macrophages, we quantified the infiltration of these cells into the
tissues. We found a significant increase (P < 0.05) in the number of
macrophages in vaginal biopsies of LET‐treated POP patients, par‐
ticularly in the sub‐SSE layer (145 ± 54 vs 33 ± 5 CD68+ cells/mm2);
and muscularis (70 ± 7 vs 31 ± 6 CD68+ cells/mm2) (Figure 6B).
F I G U R E 3 Modified Masson Trichrome staining for visualization
of total Collagen and Elastin in vaginal tissues of patients with
severe POP. A, Representative sections of vaginal biopsies showed
expression and localization of total collagen (in blue) and elastin
(in black) proteins. Magnification is 20×; scale bar 500 μm. B,
Quantification of total Collagen and Elastin in vaginal biopsy
samples from patients treated (black bars) and non‐treated with
LET (white bars), N = 5/group. Data presented as ratio of area
of collagen or elastin to the area of ROI (P < 0.05). A significant
difference is indicated by ** (P < 0.01)

CCL8, CXCL12), T cells (IL‐16, CCL2, CCL8, CXCL10, CXCL12), B cells
(CXCL13, CXCL12, CCL19) and granulocytes (IL‐16, CXCL8, CCL8).
Some play a significant role in the induction of other chemokines, such
as IFN‐γ, which can activate macrophages that produce IL1β, or induce
CXCL9, one of the most highly expressed chemokine in vaginal tissue.
The expression levels for IL‐1RA were above the range of the
standard in the Luminex assay and therefore could not be compared.
IL‐1RA is an anti‐inflammatory protein, an important member of in‐
terleukin 1 cytokine family and plays a major role in dampening in‐
flammation within different tissues in human body by antagonizing
the role of IL‐1 and IFN‐γ. ELISA quantified the expression levels of
IL‐1RA between two study groups which were not significantly dif‐
ferent (383 340.4 ± 73 584.2 pg/mL vs 289 232.3 ± 60 139.42 pg/
mL, P = 0.34) (Figure 5C). To confirm that LET also influenced tran‐
scriptional expression of vaginal cytokines, we extracted total RNA
from vaginal biopsy tissues and analysed the transcript levels of cy‐
tokines that showed high levels of protein expression and a signifi‐
cant change in between the LET and No‐LET groups (Figure 5D). All
tested genes were detected by RT‐PCR. Matching with Luminex re‐
sults, IL16, IFN‐γ, CX3CL1 and CCL3 showed a significant increase
in gene expression levels in LET‐treated samples (Figure S2).

4 | D I S CU S S I O N
Pelvic organ prolapse is a condition that affects millions of women
worldwide and significantly disrupts their quality of life. With the POP
incidence rates expected to increase with an ageing population, and
the high reoccurrence rates of this condition,2 it is important to find
therapeutic options that will help patients to enhance pelvic support.
It has been established earlier that the strength of pelvic floor de‐
pends on the ECM components of connective tissue.26 Importantly,
the symptoms of POP worsen with the decrease in circulating oes‐
trogens, implying that connective tissue of pelvic floor weakens due
to an age‐related oestrogen deprivation.27,28 The weak pelvic floor is
unable to provide proper support to pelvic organs, leading to the de‐
velopment of POP in older women.6 Thus, this study aims to examine
whether LET influences connective tissue contents of the pelvic floor
tissue in post‐menopausal women with severe grade POP.
While beneficial effects of post‐operative LET has been proven,
there is no set guideline for the pre‐operative application of LET in
POP patients due to insufficient clinical data. 29 The benefits of pre‐
operative vaginal oestrogen therapy show easier tissue handling,
cure of several concomitant symptoms and improved long‐term re‐
sults of surgery if oestrogen is continued post‐operatively.4 Recent
randomized trials have shown that there is a benefit of using LET
pre‐operatively in POP patients as it decreases degradative enzyme
activity, increases collagen content and thickness of the vaginal wall
thus improving the substrate for suture placement at time of surgical
repair and maintaining connective tissue integrity of pelvic floor.3
However, there is still a need to examine the effect of LET on mo‐
lecular levels to support its use on patients with POP as a guideline
amongst urogynaecology professionals.
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F I G U R E 4 Protein concentration of
MMPs (A, 9‐plex Luminex panel) and
TIMPs (B, 4‐plex Luminex panel) in vaginal
tissues of post‐menopausal women with
severe POP treated with LET (black
bars) and not treated (controls, white
bars). N = 19/group. Data presented as
mean ± SEM. Statistical analysis was
performed with independent sample t
test. A significant difference is indicated
by * (P < 0.05), or ** (P < 0.01)
Previous research has demonstrated that the expression of

severe POP produce lower levels of maturation enzymes BMP‐1

ECM proteins (collagen I and III30 and elastin31) is altered in pa‐

and ADMATS2 as compared to healthy controls, indicating a de‐

tients with POP as compared to asymptomatic patients with nor‐

crease in ECM quality in POP patients and an impair of the func‐

mal pelvic floor support. Additionally, the skin collagen content

tional integrity of the pelvic floor connective tissue. 39 Current

decreases by 2% in post‐menopausal women and this decrease

study demonstrates an increase in the BMP1 gene expression

correlated with oestrogen deficiency rather than with age, 33 while

following hormonal application in post‐menopausal women which

the decrease in skin elastin content is age dependent34 with elas‐

may improve the quality of vaginal ECM.

ticity decreasing by 1.5% per year. 35 Earlier studies have observed

The role of MMPs in pelvic floor disorders is well established.

that following LET treatment there was an increase in skin colla‐

MMP2 and 9 (gelatinases), MMP1, 8 and 13 (collagenases) de‐

gen content, 37 thickening of elastic fibres in the dermis, increase

grade collagen fibres; the stromelysins (MMP3 and 10) and related

in their numbers and improvement of orientation. 38 In accordance

MMPs (MMP7 and 12) are capable of degrading elastin, cell adhe‐

with previous studies, our current results show that LET can re‐

sion molecules, proteoglycans, fibronectin and laminin, suggesting

vert the menopause‐related ECM changes in vaginal skin by sig‐

their involvement in modifying the vaginal ECM. Multiple studies

nificantly improving collagen and elastin protein content in vagina

have shown that POP is associated with increase in the expression

of post‐menopausal POP patients, restoring vaginal tissue strength

of MMP1,40 MMP2 and MMP932,41 and decreases the activity of

and elasticity. It has been also reported that in patients with POP,

TIMP1‐4 leading to tissue degradation. 25,40 In our study, applica‐

there are lower levels of elastin scaffold protein fibrillin‐1 and

tion of LET resulted in a decrease in the protein expression levels of

elastin binding protein, fibulin‐5, in the peri‐urethral tissue and

MMP1, MMP2 and MMP3 an increase in TIMP1 and TIMP4. This is

uterosacral ligament. 25,36 We reported recently that patients with

in agreement with other reports which showed that HRT inhibited
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A

C

B

D

F I G U R E 5 A, Expression profile of 44 cytokines detected by Luminex assay in human vaginal tissue from post‐menopausal women with
severe POP. B, Comparative expression of 14 cytokine proteins in the LET‐treated group (black bars) and non‐treated group (control, white
bars). Concentration of chemokines was determined in 500 μg of vaginal tissue lysates. A significant difference is indicated by * (P < 0.05),
** (P < 0.01), or *** (P < 0.001). C, ELISA analysis of IL‐1RA expression (pg/mL). No significant difference was detected between the two
groups (P = 0.34). D, Analysis of cytokine gene expression between LET‐treated (black bars) and non‐treated (control, white bars) vaginal
tissue samples. The expression of cytokine genes was normalized to three housekeeping genes: TBP, YWHAZ, SDHA. Statistical analysis was
performed with independent sample t test. Data presented as mean ± SEM, N = 12

the expression and secretion of MMP2 and MMP9 in human42 and

CD4+ and CD8+ lymphocytes52, with the ratio of IFN‐γ/IL‐4 and IFN‐γ/

improved the balance of TIMP‐MMP.43 Our studies clearly indi‐

IL‐10 both significantly decreased in the older patients indicating an

cate that oestrogen limits undesirable ECM destruction by major

age‐related shift from Th1 to Th2 cytokine profiles.53 These lympho‐

degradation enzymes (MMP1, 2, 3), while not affecting the others

cytes can participate in immunoregulation, tissue remodelling, eosin‐

(MMP7‐10, 12, 13) which supports the strengthening of pelvic floor

ophil accumulation as well as induce strong antibody responses, while

tissue in post‐menopausal women.

inhibiting several functions of phagocytic cells resulting in phagocyte‐

Previous studies have shown that the immune system supports

independent inflammation. On the other hand, Th1 subsets evoke cell‐

tissue homeostasis by regulating the expression of ECM components,

mediated immunity and phagocyte‐dependent inflammation and also

ECM‐modulating enzymes and growth factors.44 Oestrogen is well

have tumour suppressive activity.54 Here, we observed an increase in

known to exert its effect on the immune system through interaction

IFN‐γ following LET which suggests that the lymphocytes attracted

with ESRs present on immune cells.14,46 Abnormalities in hormonal sta‐

to vaginal tissue might express Th1 cytokines. For instance, Yu et al

tus (such as deficiency in sex hormone) can make women susceptible

showed that increased Th1 activity directly enhances both LOX and

to various immunologic impairments.21 Similarly, the oestrogen depri‐

cross‐linked collagen.44 Shi et al45 also demonstrated that lympho‐

vation accompanying menopause is known to cause changes in the

cytes may induce tissue fibrosis by stimulating the release of TGF‐β

immune system called immunosenescence. One of the biggest age‐re‐

and regulating LOX expression in the heart. Therefore, it is possible

lated adaptation that accompany immunosenescence is the involution

that the immune cells also support tissue homeostasis.

of the thymus, resulting in fewer naïve and functionally deficient T
47-49

cells, B cells and macrophages produced.

Thus, we have tested first the basal expression of 44 soluble cy‐

Studies showed that low

tokines, within vaginal tissue samples of post‐menopausal women

levels of oestrogen in post‐menopausal women can mitigate immune

with severe POP. The exact source of these vaginal cytokine is

responses and make them susceptible to diseases and infections.21

unknown. Kumru et al measured the levels of various cytokines in

There is a systemic increase in pro‐inflammatory serum markers, IL‐6,

women following surgical menopause and found evidence of im‐

IL‐1b and TNF‐α in women after menopause that act as predictive

munodeficiency due to a decrease in the CD19+ B cell subpopula‐

markers of functional disability, fragility and mortality.50 This increase

tion, with simultaneous increase in CD8+ cells and reduced CD4/

causes a continuous stimulation of the immune system resulting in a

CD8 cell ratio.55 Studies have shown that in addition to leucocytes,

subclinical inflammatory status known as inflammaging.51

fibroblasts are capable of eliciting an immune response by direct

The effect of increasing age on type 1 (Th2) and type 2 (Th2) cy‐

communication with immune cells and by modulating the release of

tokines is challenging to study as it can be altered by many factors.

cytokines.56 The effect of pelvic floor disorders on the cytokine pro‐

Majority of studies detected increased IFN‐γ secretion by activated

duction is not fully understood. A previous study found an increase
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F I G U R E 6 Infiltration of (A) leucocytes and (B) macrophages into vaginal tissues of post‐menopausal women with severe POP. There was
a significantly (P < 0.05) higher number of CD45+ leucocytes and CD68+ macrophages (stain brown) in sub‐epithelial space (Sub‐SSE) and
muscularis layer of human vagina in women treated with LET (black bars) as compared to control women (white bars). Magnification 100×;
scale bar 100 μm. N = 10/group. A significant difference is indicated by * (P < 0.05)
in the expression levels of IL‐6, CCL2, CXCL1, CXCL2 and CXCR4

of haematopoietic precursors of granulocytes and in production

gene in patients with POP compared to asymptomatic controls.57

of other cytokines in vivo (i.e. TNF‐α). 59 Using a pan‐leucocyte

Zhao et al

58

observed an increase in the expression of IFN‐γ and

marker CD45, we confirmed that there was a significant increase

its receptors IFNGR1 and IFNGR2 in vaginal tissue of pre‐meno‐

in the total number of leucocytes infiltrating to vagina, in partic‐

pausal women with POP, suggesting that there is an association of

ular, an increase in the infiltration of CD68+ macrophages in the

inflammatory cytokines (i.e. IFN‐γ) and POP. It is however not clear

sub‐epithelial and muscularis layers. A few studies have reported

whether cytokines play a regulatory role in POP development or

the presence of inflammatory cells in the levator ani muscle and

they are a consequence of chronic inflammatory response caused

vaginal tissue of women with POP. 25,40 Earlier we observed co‐

by tissue prolapse.
Next, we examined the effect of LET on vaginal cytokines

expression of LOXL1 in CD68+ macrophages infiltrating vaginal
tissue of pre‐menopausal women with POP.41

in post‐menopausal women with severe POP and recorded an

Based on the vaginal cytokine profile, we speculate that the

increase in 14 cytokines all capable of mediating pro‐inflamma‐

invading immune cells are a mix of both major macrophage phe‐

tory responses. We suggested that these chemokines may in‐

notypes, M1 (which elucidates type 1 inflammation response and

duce chemotaxis of monocytes/macrophages (MIP1b, IFN‐γ,

antimicrobial activity), and M2 (which plays a role in ECM depo‐

IL16, IP‐10, CCL2, CCL3, CCL8, CXCL12, RANTES), T cells (IL16,

sition). We propose that this influx might increase protection

IP‐10, CCL2, CCL8, CXCL12), B cells (CXCL13, CXCL12, CCL19)

against pathogenic vaginal microbiota, as well as strengthening of

and granulocytes (IL16, CCL8) in human vaginal tissue following

the ECM. 53 Similar to our results, previous studies of immune sys‐

LET, while G‐CSF is involved in proliferation and differentiation

tem response to HRT observed an increase in TNF‐α, 23 M‐CSF, 24
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IL‐6, 60 and IFN‐γ55 as well as induction of both M1 and M2 pheno‐
types of macrophage.

8.

5 | CO N C LU S I O N

9.

There has been discussion about the efficacy of LET as a potential
supplemental agent for post‐menopausal POP patients improv‐

10.

ing the quality of their pelvic floor. The data presented here dem‐
onstrate an increase in the amount of structural proteins, collagen
and elastin, up‐regulation of their synthesis enzyme, coupled with a
decrease in their degradation enzymes, suggesting a strengthening

11.
12.

effect of oestrogen on the pelvic tissue ECM. In addition, our results
show that LET plays an important role in the activation of immune
system within the local vaginal environment, therefore resisting
menopause‐related changes and in improving urogenital tract tissue

13.
14.

regeneration. Moreover, several studies demonstrate that low‐dose
LET improves vaginal symptoms in women with history of breast
cancer with plasma estradiol levels remained in the normal range for
post‐menopausal women.

61

Altogether, our results show that LET

plays a protective role in pelvic tissue by limiting the undesirable ef‐

15.
16.

fects of age and hypoestrogenism and relieving the GSM symptoms
in post‐menopausal women affected by POP.
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